Home > News, Publications and Events > Events
Events
Duane Morris Of Counsel Arthur Dresner to Speak at the Center for Business Intelligence's 2nd Annual Pharmaceutical Congress on Paragraph IV Disputes and Settlements
October 22, 2009 | Philadelphia
| Doubletree Hotel Philadelphia
Duane Morris of counsel Arthur M. Dresner will be speaking at the Center for Business Intelligence's (CBI) 2nd Annual Pharmaceutical Congress on Paragraph IV Disputes and Settlements, to be held on October 22-23, 2009, in Philadelphia, Pennsylvania. The conference will focus on how to effectively navigate regulations, case law, reverse payment issues and enforcement trends. Mr. Dresner will participate in the spotlight session, discussing how to "Gain Insight on Biosimilars Legislation and What It Means for Industry," occurring on October 22 at 4:30 p.m.
For the biopharmaceutical industry, one of the most important, if not the most important, pieces of legislation expected to be adopted this year is for the creation of a regulatory pathway to approve biosimilars. This pathway, and the methods for patent dispute and resolution within it, has been hailed by some to have widespread and long-term implications for the way patent disputes are handled and litigated across industry. This session discusses the current bills before the House and the Senate and what they could mean for industry. The following issues will be explored:
- Analyze patent challenge mechanisms in pending legislation
- Lessons learned from Paragraph IV patent challenges
- Evaluate antitrust provisions and settlement options
About the Conference
Paragraph IV litigation is reaching an all-time high with almost $85 billion in product sales that potentially could be affected by pending litigation and more than 25 drugs going off patent before 2012. Today's pharmaceutical companies, both brand and generic, have much at stake in this costly, complex and constantly changing area of patent litigation. CBI's 2nd Annual Pharmaceutical Congress on Paragraph IV Disputes brings both sides of the issue together for two days of presentations and panel discussions to discuss litigation strategies, statutory guidelines, current cases and their landmark decisions. This timely and valuable content is designed to provide you with the information you need to know today for better business decisions tomorrow.
Who Should Attend
You will benefit from attending this conference is you are an executive or senior-level director from brand and generic pharmaceutical companies with responsibilities in:
- Patents
- Licensing
- Intellectual Property
- Litigation
- Antitrust
- General/Corporate Counsel
- Regulatory/Legal Affairs
- Product Lifecycle Management
- Strategic Planning
- Global Brand Protection
- Business Development Executives
This conference will also benefit outside patent and IP attorneys, litigators, consultants, government representatives, judiciary representatives and IP solution and/or intelligence providers.
For more information or to register online to attend, please visit the CBI website.
